Abstract

Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.

Guidance development process

How we develop NICE technology appraisal guidance

Next review date: January 2019